Sameeksha Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sameeksha Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $218.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sameeksha Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $218.8K Trade | TransData Nexus

Sameeksha Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $218.8K Total Trade · DGFT Verified

Sameeksha Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $218.8K across 2 products in 2 therapeutic categories. Based on 7 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Trastuzumab ($200.0K), Sirolimus ($18.8K), .

Sameeksha Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Sameeksha Pharmaceuticals Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sameeksha Pharmaceuticals Private Limited? — Company Overview & Market Position

Sameeksha Pharmaceuticals Private Limited, established on May 1, 2016, is a privately held pharmaceutical company headquartered in Haveli, Maharashtra, India. The company specializes in the manufacturing, trading, and export of a diverse range of pharmaceutical formulations, including critical care, oncology, antibiotics, antivirals, cardiovascular medicines, injectables, and hormones.

The company's Corporate Identification Number (CIN) is U24302PN2016PTC164262, and it is registered under the Registrar of Companies, Pune. Sameeksha Pharmaceuticals operates as a private limited company with an authorized capital of ₹100,000 and a paid-up capital of ₹100,000.

In the fiscal year 2022–2023, Sameeksha Pharmaceuticals reported a significant financial growth, with revenue increasing by 1,196% compared to the previous year. The company's net worth also saw a substantial rise of 3,703.28% during the same period.

What Does Sameeksha Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Trastuzumab$200.0K

Product Portfolio — Top 2 by Export Value

Sameeksha Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Trastuzumab	Advanced Oncology	$200.0K	4	0.3%	8
2	Sirolimus	Immunosuppressants	$18.8K	3	0.1%	12

Sameeksha Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $218.8K. The top category is Advanced Oncology (91.4% of portfolio), followed by Immunosuppressants (8.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Sameeksha Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sameeksha Pharmaceuticals operates manufacturing facilities in Pune, Maharashtra, India. The company specializes in the production of various pharmaceutical dosage forms, including tablets, capsules, oral liquids, dry syrups, injectable vials, ampoules, creams, ointments, drops, and inhalers.

3Key Leadership

Sameeksha Pharmaceuticals is led by co-founders Mr. Samir Madhukar Gaikwad and Mrs. Samiksha Samir Gaikwad. Both have been serving as directors since the company's inception on May 1, 2016.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sameeksha Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sameeksha Pharmaceuticals has made significant strides in expanding its presence in regulated markets. The company exports finished pharmaceutical formulations to over 30 clients across regions including Africa, Latin America, the Caribbean, the Middle East, and Southeast Asia. This extensive export network indicates a robust understanding of international regulatory requirements and market dynamics.

2Emerging Markets

Sameeksha Pharmaceuticals has established export partnerships in emerging markets such as Africa, Latin America, the Caribbean, the Middle East, and Southeast Asia. The company's adherence to WHO-GMP guidelines for manufacturing suggests a commitment to meeting international quality standards, facilitating access to these markets.

3Geographic Strategy

Sameeksha Pharmaceuticals demonstrates a diversified geographic strategy by exporting to multiple regions, including Africa, Latin America, the Caribbean, the Middle East, and Southeast Asia. This approach mitigates concentration risk and positions the company to leverage growth opportunities across various markets.

Sameeksha Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available information, Sameeksha Pharmaceuticals has not reported any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), or Drug Master File (DMF) filings. The company has not disclosed its FDA inspection history. This suggests that Sameeksha Pharmaceuticals may not currently have a presence in the U.S. market.

2WHO & EU GMP

Sameeksha Pharmaceuticals manufactures its products under ISO and WHO-GMP guidelines, ensuring compliance with international quality standards. The company has not publicly disclosed EU GMP certifications or EDQM status.

3CDSCO & Indian Regulatory

Sameeksha Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has approvals from state drug controllers. The company has filed its annual financial statements for the year ended March 31, 2024, with the Registrar of Companies, Pune.

Sameeksha Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sameeksha Pharmaceuticals operates in a competitive landscape with numerous pharmaceutical companies offering similar products. The company's focus on high-quality, affordable, and accessible healthcare solutions positions it favorably in the market. However, the lack of publicly available data on market share and direct competitors makes a detailed head-to-head analysis challenging.

2Key Differentiators

Sameeksha Pharmaceuticals' commitment to quality is evident in its adherence to ISO and WHO-GMP guidelines for manufacturing. The company's diverse therapeutic portfolio, including oncology, anti-infectives, hormones, CNS, and NSAIDs, allows it to cater to a wide range of patient needs. Additionally, Sameeksha Pharmaceuticals' extensive export partnerships across multiple regions demonstrate its global reach and operational capabilities.

3Strategic Position

Sameeksha Pharmaceuticals is strategically positioned as a manufacturer and exporter of finished pharmaceutical formulations, focusing on a diverse therapeutic portfolio. The company's significant revenue growth in the fiscal year 2022–2023 indicates a strong market presence and operational efficiency. Future strategic directions may include expanding into new markets, enhancing research and development capabilities, and strengthening regulatory compliance to support sustained growth.

Buyer Due Diligence Brief — Evaluating Sameeksha Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sameeksha Pharmaceuticals has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's export value of $219,000 USD across seven shipments, with a portfolio concentration of 100% in its top five products, indicates a focused approach to its product offerings. The significant revenue growth in the fiscal year 2022–2023 reflects the company's reliability and appeal as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Sameeksha Pharmaceuticals as a supplier:

WHO-GMP Certification: Ensures compliance with international manufacturing standards.

ISO Certification: Indicates adherence to quality management systems.

EU GMP Certification: If applicable, confirms compliance with European manufacturing standards.

Frequently Asked Questions — Sameeksha Pharmaceuticals Private Limited

How many pharmaceutical products does Sameeksha Pharmaceuticals Private Limited export from India?

Sameeksha Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Trastuzumab ($200.0K), Sirolimus ($18.8K). Total export value is $218.8K.

What is Sameeksha Pharmaceuticals Private Limited's total pharmaceutical export value?

Sameeksha Pharmaceuticals Private Limited's total pharmaceutical export value is $218.8K, based on 7 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Sameeksha Pharmaceuticals Private Limited cover?

Sameeksha Pharmaceuticals Private Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (91.4%, 1 products), Immunosuppressants (8.6%, 1 products).

Get Full Sameeksha Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.